Clinical Trial Update: Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia [NA]

View source ↗

Summary

This entry notes a multicenter platform-type clinical study for refractory/recurrent acute myeloid leukemia in China, currently in the recruiting stage.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: AML, Refractory | NA | Status: RECRUITING